Criado-álvarez, J.J., González González, J., Romo Barrientos, C., Mohedano Moriano, A., Montero Rubio, J.C. and Pérez Veiga, J.P. (2016) Variability and Trends in the Consumption of Drugs for Treating Attention-Deficit/Hyperactivity Disorder in Castile-La Mancha, Spain (1992-2015). Neurologia, Article ID: pii: S0213-4853(16)30171-2.

has been cited by the following article:

• TITLE: Is the Treatment of Attention Deficit Hyperactivity Disorder a New Cause of Cataract?

  AUTHORS: Mujdat Karabulut, Sinem Karabulut, Tolga Kocatürk, Seyhan Bahar Ozkan

  KEYWORDS: Attention Deficit Hyperactivity Disorder, Methylphenidate, Cataract

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.8 No.1, February 5, 2018

  ABSTRACT: Attention deficit hyperactivity disorder (ADHD) is the most common behavioral disorder of childhood and it has 5% prevalence among children worldwide [1]. In the treatment of ADHD stimulant medications are recommended as the first choice of pharmacotherapy [2]. Methylphenidate-HCl is a sympathomimetic amine derivative pharmacological agent; and it is widely used in the treatment of ADHD. Although there are some articles showing that oral methylphenidate increases the risk of glaucoma [3], to the best of our knowledge, there is only one case report that indicates a possible relation of methylphenidate treatment and cataract formation [4].